TLSA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of earnings and positive book value utility.
- P/B ratio of 15.71 is excessive for a non-earning entity
- No P/E or PEG available due to lack of earnings
Future value is entirely dependent on binary clinical trial outcomes.
- High analyst target price suggests potential clinical catalyst
- No historical revenue or earnings growth to project from
Long-term trend is decisively negative.
- 1-year return is slightly positive (+7.1%)
- 5-year change is -51.0%
- 6-month change is -38.3%
Liquidity is currently stable, but operational health is failing.
- Low Debt/Equity
- Current Ratio > 1.5
- Piotroski F-Score of 3/9 indicates weak financial health
- Severe negative ROA
Company is in a growth/burn phase; dividends are not applicable.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TLSA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd
Primary
|
-51.0% | +16.4% | +7.1% | -38.3% | 0.0% | +5.2% |
|
TKNO
Alpha Teknova, Inc.
Peer
|
-88.4% | +41.3% | -49.6% | -49.4% | +4.3% | -3.6% |
|
RCEL
AVITA Medical, Inc.
Peer
|
-74.5% | -65.7% | -44.2% | +28.8% | +22.7% | +2.6% |
|
APYX
Apyx Medical Corporation
Peer
|
-68.5% | +28.3% | +249.0% | +72.9% | -7.4% | +16.4% |
|
SPRO
Spero Therapeutics, Inc.
Peer
|
-77.5% | +57.1% | +264.7% | +24.4% | +11.8% | +3.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2024
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd
|
BEARISH | $153.97M | - | -232.3% | -% | $1.21 | |
|
TKNO
Alpha Teknova, Inc.
|
BEARISH | $155.94M | - | -22.8% | -42.6% | $2.91 | Compare |
|
RCEL
AVITA Medical, Inc.
|
BEARISH | $157.45M | - | -% | -67.8% | $5.14 | Compare |
|
APYX
Apyx Medical Corporation
|
BULLISH | $148.94M | - | -76.1% | -21.2% | $3.63 | Compare |
|
SPRO
Spero Therapeutics, Inc.
|
BEARISH | $159.2M | 18.33 | 16.3% | 12.8% | $2.75 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Tesla filed its 20-F annual report on May 6, 2025, providing a comprehensive overview of its yearly financial performance and operational highlights. The filing contains detailed disclosures regarding the company's financial position and the primary risk factors impacting its business operations.
Past News Coverage
Recent headlines mentioning TLSA from our newsroom.